Clinical trial • Phase I • Endocrinology

PF-07999415

Phase I trial of PF-07999415. 53 participants.

Overview

Trial Therapeutic Area
Endocrinology
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
10-04-2025
First CTIS Authorization Date
13-06-2025

Trial design

Phase I trial across 1 site in Belgium.

Target Sample Size
53

Eligibility

Recruits 53 No vulnerable population selected; participants are healthy adult volunteers; assent/consent handling not detailed in the record..

Vulnerable Population
No vulnerable population selected; participants are healthy adult volunteers; assent/consent handling not detailed in the record.

Recruitment

Planned Sample Size
53
Recruitment Window Months
8
Consent Approach
Not specified in the record; participants are healthy adults; informed consent process, assent handling, and languages are not detailed.

Methods

  • Site-based recruitment via Pfizer Clinical Research Unit (Brussels, Belgium) with contact email PfizerVolRecruitment@pfizer.com and phone +3225567003 targeting healthy volunteers.

Geography

Total Number Of Sites
1
Total Number Of Participants
53

Belgium

Earliest CTIS Part Ii Submission Date
05-05-2025
Latest Decision Or Authorization Date
23-01-2026
Processing Time Days
263
Number Of Sites
1
Number Of Participants
53

Sites

Site Name
Pfizer Clinical Research Unit
Contact Person Name
Alexandre Stouffs
Number Of Participants
53

Sponsor

Primary sponsor

Full Name
Pfizer Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
PF-07999415

Related trials

Other published trials that may interest you.